复方血栓通联合云南白药治疗玻璃体积血疗效分析

Compound Xueshuantong capsule combining yunnan Bai Yao for vitreous hemorrhage

目的评估复方血栓通联合云南白药治疗玻璃体积血的疗效及可行性。方法2005年12月至2007年7月我院收治的58例(58只眼)玻璃体积血,随机分成四组,分别给予治疗。Ⅰ组为常规治疗组(13只眼);Ⅱ组为云南白药治疗组(14只眼);Ⅲ组为复方血栓通胶囊治疗组(14只眼);Ⅳ组为Ⅱ、Ⅲ联合疗法组(17只眼)。根据如下疗效判断标准:①治愈:最佳矫正视力提高≥5行不伴玻璃体积血;②显效:最佳矫正视力提高≥3行,玻璃体积血基本干净,无纤维条索形成;③有效:最佳矫正视力提高≥1行,伴有限的玻璃体纤维条索形成;④未愈:最佳矫正视力无提高,伴显著的玻璃体纤维条索形成或并发增生性玻璃体视网膜病变或新生血管性青光眼。结果随访3个月后,49只眼最佳矫正视力提高,总有效率77.59%,显效率56.90%。Ⅰ组与Ⅱ、Ⅲ、Ⅳ组间差别有统计学意义,Ⅱ组与Ⅲ组间无统计学意义,Ⅱ组与Ⅳ组、Ⅲ组与Ⅳ组有统计学意义的差别。6只眼出现玻璃体增生纤维条索牵引,5只眼玻璃体积血浓厚,1只眼出现新生血管性青光眼。结论复方血栓通联合云南白药治疗玻璃体积血的疗效显著,能明显消除积血,改善患者视力。

Objective To evaluate the feasibility and effects of compound Xueshuantong capsule combining Yunnan Bai Yao for vitreous hemorrhage. Methods A Total 58 eyes in 58 patients with vitreous hemorrhage during Dec, 2005 to July, 2007 were randomized into 4 groups ： group Ⅰ, routin treatment group used vitamins mainly （ n = 13 ） ; group Ⅱ, Yunnan Bai Yao group （ n = 14 ） ; group Ⅲ, compound Xueshuantong capsule group （ n = 14 ） ; and group Ⅳ, combined treatment group united group Ⅱ and Ⅲ （ n = 17 ）. All latter 3 groups were treated based by the way of group Ⅰ. A series of tests would be done anti-and post-therapy, and the curative effects between groups would be decided aeording to：（1）eured： the improvement of best correct visual acuity （ BCVA） ≥5 lines without any visual vitreous blood; （2）effective ：the improvement of BCVA≥3 lines without any visual vitreous blood or fibrotie tissue; （3）improved： the improvement of BCVA ≥1 lines with limited vitreous perliferating; （4）tmeured： no BCVA improved with a distinct vitreous perliferating or neovusalar glaucoma. Results A total 49 eyes were improved in BCVA, with a whole improved ratio of 77.59% and effective ratio 56.90% during the follow-up of 3 months. The difference within groups using ridit analysis implied that there is a clinical significant difference between group Ⅰ and other groups without any difference between group Ⅱ and Ⅲ, whileas, group Ⅳ is better than group Ⅱ and Ⅲ seperatively. Vitreous showed in 6 eyes while the vitrous cavity of 5 eyes were still filled with blood and 1 eyes occurred neovascular glaucoma. Conclusion Compound Xueshuantong capsule combining Yunnan Bai Yao can effectively raise the absorption of vitreous blood with BCVA improved finally. The curative effect in combining treatmnet group is distinctly better than that of other groups.